Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

Low frequency of hCDC4 mutations in human primary ovarian cancer.

Sgambato A, Cittadini A, Masciullo V, Di Salvatore M, Graziani C, Rettino A, Valdivieso P, Scambia G, Bianchino G, Zupa A, Improta G, Cifarelli RA.

Gynecol Oncol. 2007 May;105(2):553-5. Epub 2007 Feb 23. No abstract available.

PMID:
17320938
2.

Infrequent mutations of Archipelago (hAGO, hCDC4, Fbw7) in primary ovarian cancer.

Kwak EL, Moberg KH, Wahrer DC, Quinn JE, Gilmore PM, Graham CA, Hariharan IK, Harkin DP, Haber DA, Bell DW.

Gynecol Oncol. 2005 Jul;98(1):124-8.

PMID:
15913747
3.

Mutational analysis of the hCDC4 gene in gastric carcinomas.

Lee JW, Soung YH, Kim HJ, Park WS, Nam SW, Kim SH, Lee JY, Yoo NJ, Lee SH.

Eur J Cancer. 2006 Sep;42(14):2369-73. Epub 2006 Jul 5.

PMID:
16824748
4.

Somatic mutation of hCDC4 gene is rare in lung adenocarcinomas.

Woo Lee J, Hwa Soung Y, Young Kim S, Woo Nam S, Sang Park W, Young Lee J, Jin Yoo N, Hyung Lee S.

Acta Oncol. 2006;45(4):487-8. No abstract available.

PMID:
16760187
5.

The Fbxw7/hCdc4 tumor suppressor in human cancer.

Tan Y, Sangfelt O, Spruck C.

Cancer Lett. 2008 Nov 18;271(1):1-12. doi: 10.1016/j.canlet.2008.04.036. Epub 2008 Jun 9. Review.

PMID:
18541364
6.

Mutation of hCDC4 leads to cell cycle deregulation of cyclin E in cancer.

Ekholm-Reed S, Spruck CH, Sangfelt O, van Drogen F, Mueller-Holzner E, Widschwendter M, Zetterberg A, Reed SI.

Cancer Res. 2004 Feb 1;64(3):795-800. Erratum in: Cancer Res. 2004 Apr 15;64(8):2939. Reed, Susanna Ekholm [corrected to Reed-Ekholm, Susanna].

7.

hCDC4 gene mutation is rare in colorectal carcinomas in Korean patients.

Lee JW, Jeong EG, Lee SH, Yoo NJ, Lee SH.

Pathology. 2008 Apr;40(3):305. doi: 10.1080/00313020701813693. No abstract available.

PMID:
18428053
8.

The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling.

Malyukova A, Dohda T, von der Lehr N, Akhoondi S, Corcoran M, Heyman M, Spruck C, Grandér D, Lendahl U, Sangfelt O.

Cancer Res. 2007 Jun 15;67(12):5611-6. Erratum in: Cancer Res. 2008 Mar 15;68(6):2051. Akhondi, Shahab [corrected to Akhoondi, Shahab].

9.

hCDC4 variation in osteosarcoma.

Yan T, Wunder JS, Gokgoz N, Seto KK, Bell RS, Andrulis IL.

Cancer Genet Cytogenet. 2006 Sep;169(2):138-42.

PMID:
16938571
10.

Cyclin E gene (CCNE) amplification and hCDC4 mutations in endometrial carcinoma.

Cassia R, Moreno-Bueno G, Rodríguez-Perales S, Hardisson D, Cigudosa JC, Palacios J.

J Pathol. 2003 Dec;201(4):589-95.

PMID:
14648662
11.

FBXW7/hCDC4 is a general tumor suppressor in human cancer.

Akhoondi S, Sun D, von der Lehr N, Apostolidou S, Klotz K, Maljukova A, Cepeda D, Fiegl H, Dafou D, Marth C, Mueller-Holzner E, Corcoran M, Dagnell M, Nejad SZ, Nayer BN, Zali MR, Hansson J, Egyhazi S, Petersson F, Sangfelt P, Nordgren H, Grander D, Reed SI, Widschwendter M, Sangfelt O, Spruck C.

Cancer Res. 2007 Oct 1;67(19):9006-12. Erratum in: Cancer Res. 2008 Feb 15;68(4):1245. Dofou, Dimitra [corrected to Dafou, Dimitra].

12.

Genetic susceptibility to the development and progression of breast cancer associated with polymorphism of cell cycle and ubiquitin ligase genes.

Yu JC, Ding SL, Chang CH, Kuo SH, Chen ST, Hsu GC, Hsu HM, Hou MF, Jung LY, Cheng CW, Wu PE, Shen CY.

Carcinogenesis. 2009 Sep;30(9):1562-70. doi: 10.1093/carcin/bgp173. Epub 2009 Jul 8.

PMID:
19587092
13.

FBXW7 gene mutation is rare in acute leukemia samples of Korean patients.

Jeong EG, Kim MS, Kim SH, Yoo NJ, Lee SH.

Acta Haematol. 2007;118(4):200-2. Epub 2007 Nov 9. No abstract available.

PMID:
17992009
14.

Inactivation of hCDC4 can cause chromosomal instability.

Rajagopalan H, Jallepalli PV, Rago C, Velculescu VE, Kinzler KW, Vogelstein B, Lengauer C.

Nature. 2004 Mar 4;428(6978):77-81.

15.

hCDC4 gene mutations in endometrial cancer.

Spruck CH, Strohmaier H, Sangfelt O, Müller HM, Hubalek M, Müller-Holzner E, Marth C, Widschwendter M, Reed SI.

Cancer Res. 2002 Aug 15;62(16):4535-9.

16.

Dosage and tumour suppression.

Berger AH, Knudson AG, Pandolfi PP.

J Pathol. 2012 Jun;227(2):e1; author reply e2. doi: 10.1002/path.4035. No abstract available.

PMID:
22488586
17.

NOTCH mutations as prognostic markers in T-ALL.

Ferrando A.

Leukemia. 2010 Dec;24(12):2003-4. doi: 10.1038/leu.2010.237. No abstract available.

PMID:
21157484
18.

Fbxw7 hotspot mutations and human colon cancer: mechanistic insights from new mouse models.

Grim JE.

Gut. 2014 May;63(5):707-9. doi: 10.1136/gutjnl-2013-305144. Epub 2013 Sep 2. No abstract available.

PMID:
24000292
19.

The methylation status of FBXW7 beta-form correlates with histological subtype in human thymoma.

Gu Z, Mitsui H, Inomata K, Honda M, Endo C, Sakurada A, Sato M, Okada Y, Kondo T, Horii A.

Biochem Biophys Res Commun. 2008 Dec 12;377(2):685-8. doi: 10.1016/j.bbrc.2008.10.047. Epub 2008 Oct 18.

PMID:
18938137
20.

Mutations of NOTCH1, FBXW7, and prognosis in T-lineage acute lymphoblastic leukemia.

Mullighan CG.

Haematologica. 2009 Oct;94(10):1338-40. doi: 10.3324/haematol.2009.012047. No abstract available.

Supplemental Content

Support Center